The pharmaceutical sector has grown by an average annual rate of 8% over the last decade, reaching RM8.6 billion or 16.5% of total healthcare expenditure (RM52 billion) in 2016. Imported medicines at RM5.4 billion still account for the largest part (63%) of the RM8.6 billion pharmaceutical market, while exports are only RM0.7 billion. Generic medicines now account for 55% of the controlled (prescription) medicines market by value.
The market structure of Malaysia’s pharmaceutical sector is characterized by a three-level supply chain, starting with manufacturers of generic medicines and importers of originator and generic medicines at the first level, wholesalers and distributors at the second level, and providers at the third level who provide medicines to patients and end users.
Table of Contents
PART ONE: Overview of Malaysia’s Pharmaceutical Sector
Chapter 1: Overall Growth of the Healthcare and Pharmaceutical Sectors
Chapter 2: Market Structure and Supply Chain
Chapter 3: Market Share and Market Concentration
Chapter 4: Market Dominance and Impact on Availability,
Affordability and Accessibility of Medicines
PART TWO: Competition Concerns in the Pharmaceutical Sector
Chapter 5: Key Existing Laws and Regulations and An Assessment of Impacts
Chapter 6: Competition Concerns Among Industry Players
Chapter 7: Selected Case Studies on Anti-Competitive Conduct
PART THREE: Conclusion and Recommendations
Tables and Figures